Evofem Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Product sales, net | $899 | $845 |
| Operating Expenses (Benefits): | ||
| Cost of goods sold | 410 | 365 |
| Amortization of intangible asset | 75 | 223 |
| Research and development, net | 518 | (5,035) |
| Selling and marketing | 2,093 | 2,600 |
| General and administrative | 2,372 | 2,365 |
| Total operating expenses | 5,468 | 518 |
| Income (loss) from operations | (4,569) | 327 |
| Other income (expense): | ||
| Interest income | 2 | 8 |
| Other expense, net | (737) | (600) |
| Change in fair value of financial instruments | (162) | 1,221 |
| Total other income (expense), net | (897) | 629 |
| Income (loss) before income tax expense | (5,466) | 956 |
| Income tax expense | 1 | - |
| Net income (loss) | (5,465) | 956 |
| Convertible and redeemable preferred stock deemed dividends | (20) | (3) |
| Net income (loss) attributable to common stockholders | $(5,485) | $953 |
| Net income (loss) per share attributable to common stockholders: | ||
| Basic | $(0.04) | $0.01 |
| Diluted | $(0.04) | $0.00 |
| Weighted-average shares used to compute net income (loss) per share attributable to common shareholders: | ||
| Basic | 133,246,864 | 118,164,046 |
| Diluted | 133,246,864 | 6,155,035,291 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.